|Tested species reactivity||Human, Mouse|
|Published species reactivity||Human|
|Host / Isotype||Rabbit / IgG|
|Immunogen||A synthetic 19-mer peptide, corresponding to aa 8-26 (VKPPQNKTESENTSDKPKR) from the secreted amphiregulin of human origin|
|Storage buffer||PBS, pH 7.4, with 0.2% BSA|
|Contains||0.09% sodium azide|
|Storage Conditions||4° C|
|Tested Applications||Dilution *|
|Immunoprecipitation (IP)||10 µg/ml|
* Suggested working dilutions are given as a guide only. It is recommended that the user titrate the product for use in their own experiment using appropriate negative and positive controls.
|Immunohistochemistry (IHC)||See 1 publications below|
PA5-16616 targets Amphiregulin in IP applications and shows reactivity with Human and mouse samples.
The PA5-16616 immunogen is a synthetic 19-mer peptide, corresponding to aa 8-26 (VKPPQNKTESENTSDKPKR) from the secreted amphiregulin of human origin.
Amphiregulin (AR) binds to EGF-Receptor (EGFR) with lower affinity than EGF. The mature secreted form AR is an 84-amino acid residue glycosylated polypeptide growth regulator, which is generated by proteolytic processing of a 252-amino acid transmembrane precursor. Seven different polypeptide ligands, which derive from distinct genes, are capable of binding to the extracellular domain of EGFR. These ligands include EGF, TGFalpha, AR, HB-EGF, cripto-1, epiregulin, and beta cellulin. All of these growth factors contain a characteristic EGF-like domain which is defined by six evenly spaced cysteine residues that generate three loops through the formation of disulfide bonds. AR protein has been localized by immunohistochemistry to the epithelium of the colon, stomach, pancreas, breast, and placenta. AR is reportedly overexpressed in human cancers of breast, colon, stomach, and pancreas.
For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.
Expression of the epidermal growth factor system in human middle ear cholesteatoma.
PA5-16616 was used in immunohistochemistry to study the expression of the EGFR system in patients with middle ear cholesteatoma
|Thorup MB,Munk M,Poulsen SS,Gaihede M,Nexo E,Sorensen BS,Ovesen T||Acta oto-laryngologica (134:124)||2014|